LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.325
+0.015 (1.15%)
Jun 23, 2025, 4:00 PM - Market closed
LAVA Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover LAVA Therapeutics stock have a consensus rating of "Hold" and an average price target of $1.75, which forecasts a 32.08% increase in the stock price over the next year. The lowest target is $1.5 and the highest is $2.
Price Target: $1.75 (+32.08%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
The average analyst rating for LAVA Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 15, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1.5 | Hold | Reiterates | $1.5 | +13.21% | Mar 31, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $2 → $1.5 | Strong Buy → Hold | Downgrades | $2 → $1.5 | +13.21% | Feb 27, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $2 | Strong Buy | Maintains | $6 → $2 | +50.94% | Dec 20, 2024 |
Leerink Partners | Leerink Partners | Buy → Hold Downgrades $11 → $2 | Buy → Hold | Downgrades | $11 → $2 | +50.94% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
n/a
from 11.98M
Revenue Next Year
n/a
EPS This Year
-1.14
from -0.94
EPS Next Year
-0.81
from -1.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.88 | -0.49 | -0.27 | ||
Avg | -1.14 | -0.81 | -0.38 | ||
Low | -1.55 | -1.09 | -0.47 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.